Earnings ·
Exelixis reported second quarter 2026 financial results with total revenues of $628.7 million and net product revenues…
EXELExelixis, Inc.
Exelixis reported second quarter 2026 financial results with total revenues of $628.7 million and net product revenues of $573.0 million, driven by a $573.0 million contribution from the cabozantinib franchise in the U.S. GAAP diluted EPS was $0.82, while non-GAAP diluted EPS reached $0.91. The company updated its full-year 2026 guidance, lowering total revenue expectations to $2.500 billion–$2.550 billion and R&D expenses to $825 million–$875 million. Exelixis completed a $750 million stock repurchase program authorized in October 2025 and received Board approval for an additional $750 million buyback through December 31, 2027. Pipeline updates included the FDA-assigned PDUFA date of December 3, 2026, for zanzalintinib in metastatic colorectal cancer and ongoing pivotal trials for various oncology indications. Exelixis is a biopharmaceutical company focused on discovering and developing targeted therapies for cancer.